Abilify breaks $1bn barrier in US quarterly sales
This article was originally published in Scrip
Executive Summary
US net sales of Abilify (aripiprazole) rose by 14% to just over $1.0 billion in the second quarter ended 30 June, helped by new indications for the atypical antipsychotic, new unaudited figures from originator Otsuka show.